Ozempic (semaglutide) has been associated with a very low risk of thyroid cancer, specifically medullary thyroid cancer (MTC). In earlier laboratory studies, researchers observed an increased incidence of MTC in rodents exposed to semaglutide. However, these findings have not been conclusively replicated in human studies.
Has Ozempic been linked to thyroid cancer? A recent study from Denmark, Norway, and Sweden involving over 435,000 participants found no evidence that GLP-1 receptor agonists like Ozempic increase the risk of thyroid cancer.
Despite these findings, the U.S. Food and Drug Administration (FDA) has issued a warning regarding the potential risk of thyroid tumors with GLP-1 receptor agonists. The warning advises patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2) to avoid semaglutide medications.
In summary, while laboratory studies have suggested a potential link between Ozempic and thyroid cancer, human studies have not confirmed this association. The FDA’s warning reflects a precautionary approach due to the findings in animal studies. Individuals with a personal or family history of MTC or MEN2 should consult their healthcare provider before using Ozempic.
1-800-870-8910